Skip to main content
Menu

Main navigation

  • About
    • Annual Reports
    • Leadership
    • Jobs
    • Student Programs
    • Media Information
    • Store
    • Contact
    LOADING...
  • Experts
    • Policy Scholars
    • Adjunct Scholars
    • Fellows
  • Events
    • Upcoming
    • Past
    • Event FAQs
    • Sphere Summit
    LOADING...
  • Publications
    • Studies
    • Commentary
    • Books
    • Reviews and Journals
    • Public Filings
    LOADING...
  • Blog
  • Donate
    • Sponsorship Benefits
    • Ways to Give
    • Planned Giving

Issues

  • Constitution and Law
    • Constitutional Law
    • Criminal Justice
    • Free Speech and Civil Liberties
  • Economics
    • Banking and Finance
    • Monetary Policy
    • Regulation
    • Tax and Budget Policy
  • Politics and Society
    • Education
    • Government and Politics
    • Health Care
    • Poverty and Social Welfare
    • Technology and Privacy
  • International
    • Defense and Foreign Policy
    • Global Freedom
    • Immigration
    • Trade Policy
Live Now

Cato at Liberty


  • Blog Home
  • RSS

Email Signup

Sign up to have blog posts delivered straight to your inbox!

Topics
  • Banking and Finance
  • Constitutional Law
  • Criminal Justice
  • Defense and Foreign Policy
  • Education
  • Free Speech and Civil Liberties
  • Global Freedom
  • Government and Politics
  • Health Care
  • Immigration
  • Monetary Policy
  • Poverty and Social Welfare
  • Regulation
  • Tax and Budget Policy
  • Technology and Privacy
  • Trade Policy
Archives
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • Show More
September 13, 2016 11:20AM

The Incoherence of Schedule I

By Jason Kuznicki

SHARE

Drug policy watchers learned earlier this month that the latest substance to earn Schedule I status is the obscure plant ​called kratom. So what's Schedule I? By the letter of the law, Schedule I of the Controlled Substances Act contains "drugs, substances, or chemicals" that meet the following criteria:

The drug or other substance has a high potential for abuse.
The drug or other substance has no currently accepted medical use in treatment in the United States.
There is a lack of accepted safety for use of the drug or other substance under medical supervision.

In this post, I'm not going to consider the penalties that apply to the use, possession, or sale of Schedule I substances. I'm just going to look at the criteria for inclusion. While they may appear plausible, these criteria are preposterous and completely indefensible as applied.

The most important unwritten fact about Schedule I is that all three of its criteria are terms of political art. Neither science nor the plain meanings of the words have much to do with what Schedule I really includes.

We can see this first in how Schedule I fails to include many substances that clearly belong there. These substances easily meet all three criteria. Yet they are in no danger whatsoever of being scheduled. It literally will never happen.

Solvent inhalants, such as toluene, have a high potential for abuse, have no accepted medical uses, and cannot be used safely even with close medical supervision. The same is true of obsolete anesthetics like diethyl ether and chloroform. Toluene, ether, and chloroform are all dangerous when used as drugs. Overdosing on each is relatively easy, they bring serious health risks at any level of use, and they have no valid medical uses today.

None, of course, will ever be scheduled, because each is also an essential industrial chemical. That they happen to be abusable as drugs is a fact that a crime-based drug policy can't easily accommodate. And so that fact is simply ignored.

The substances included on Schedule I are an odd lot as well. Some clearly meet the criteria, but many do not.

Why, for example, is fenethylline Schedule I, while amphetamine is in the less restrictive Schedule II? On ingestion, fenethylline breaks down into two other compounds: theophylline -- a caffeine-like molecule found in chocolate -- and amphetamine.

People commonly use amphetamine under medical supervision in the United States; the popular ADHD drug Adderall is simply a mixture of various forms of amphetamine. Theophylline has also seen use by physicians for care of various respiratory issues. And people still use fenethylline under medical supervision in other countries. In the published literature, fenethylline is described as having a "lower abuse potential and little actual abuse compared to amphetamine." (Emphasis added.) To say that fenethylline has "no accepted medical use in the United States" is, quite literally, to suggest that medical science changes when you cross the border.

​Fenethylline isn't unique. Schedule I contains many drugs quite like it, molecules that bear a close but not exact resemblance to familiar and widely used medical drugs. Many of these are prodrugs -- substances that break down in the body to become familiar, medically useful molecules like morphine or amphetamine. Others, like dimethylamphetamine, are held by the medical literature to be safer than their less strictly regulated chemical cousins.

This is not to say that fenethylline, dimethylamphetamine, or amphetamine itself is risk-free. No drug is. But one could hardly find a less rational set of classifications than this one, in which drugs are scheduled more severely if and when they are less risky.

O​r consider psilocybin. ​Psilocybin flunks the first criterion for Schedule I because it is in fact fairly difficult to abuse. Psilocybin​ ​binges don't generally happen because even a single dose creates a swift and strong tolerance response: A second dose, or an added dose of any other traditional psychedelic, usually does little or nothing, and doses after that will likely be inert until several days have elapsed.

A user may have a regrettable or upsetting psilocybin​ ​experience, and many do. But users can't have a binge, and deaths and serious illnesses are exceedingly rare. Psilocybin isn't an entirely risk-free drug -- again, no drug is risk-free -- but it's clearly not in the same league as cocaine (Schedule II) or even ketamine (Schedule III). Going by the letter of the law, psilocybin's place on Schedule I is inexplicable.

Still more inexplicable is cannabis, which has​ a relatively low ​potential for abuse, ​many important medical uses, ​and ​​such a favorable safety profile that a life-threatening overdose is impossible. Too much cannabis can be deeply psychologically unpleasant, but it can't be fatal.

As you all know, cannabis is Schedule I.

This has brought Americans, long the world's most inventive people, to invent and ingest dozens of substitutes. Each of these so-called cannabimimetics became a recreational drug almost solely because a safe, well-studied, and well-tolerated recreational drug -- cannabis -- just happened to be illegal. Now there are dozens of cannabimimetics, all with somewhat different dosages, effects, and safety profiles. Much remains unknown about them, unlike the relatively well-studied compounds found in cannabis.

A similar process has taken place with the traditional psychedelics, generating a bewildering array of new psychoactive substances, each of which has a dosage, effect constellation, and risk profile that is relatively unknown when compared to, say, psilocybin or mescaline. It might even be said that Schedule I itself is the single largest cause of Schedule I drugs. In all, the mimetics are an area of comparative ignorance. Many of these new drugs may even deserve a bad reputation, if not a state-enforced ban. But, at least for a time, all of them were technically legal (at least, if we ignore the Federal Analogue Act, which is an entirely different mess of its own). If cannabis or psilocybin were legal instead, few would likely bother with the mimetics outside a laboratory setting.

Yet many of these mimetics could also be medically interesting, much like cannabis itself. We just don't know yet, and we are a lot less likely ever to find out because it's difficult to do research with Schedule I drugs.

To sum up, the list of drugs on Schedule I both over-includes and under-includes. I suspect that the list does not exist to fulfill the criteria. Rather, the criteria​ exist to make Congressional and DEA determinations look scientific, even when they clearly are not. They would appear to have no other function.

With that in mind, let's take a closer look at kratom.

Mitragyna speciosa, known as kratom.

As Jacob Sullum notes, the DEA has simply defined all use of kratom as abuse. Of course, then, the potential for abuse is (nominally) high. But it begs the question that science could and should have answered: What exactly is kratom's abuse potential? Thanks to kratom's new Schedule I status, U.S. researchers are in no position to question the DEA anytime soon.

This is typical of how drug scheduling works; to some extent the law creates its own medical facts by foreclosing research avenues that might otherwise be explored. But it can only do this by stunting our knowledge and perhaps delaying the development of useful new medicines.

What's true of abuse potential is also true of "accepted medical use." It too is an obfuscation; the DEA, and not doctors, determine what counts as accepted. But as Jeffrey Miron noted, kratom users report that it can relieve the symptoms of opiate addiction and help addicts kick the habit. Are they right? More clinical study might help, and we can be pretty sure that we're not getting it now.

Finally, "lack of accepted safety for use" is -- you guessed it -- yet another determination made by a certain department in the executive branch. Not that it would change their minds, but Jacob Sullum correctly notes that kratom is relatively safe when compared to many other drugs, particularly the recreational opiates like heroin. In particular, while overdose on kratom is certainly possible, no fatal overdoses have ever been recorded. This is not to say that it's impossible, of course, but when compared to heroin -- or many other drugs -- "no recorded fatal overdoses" is a pretty good track record.

In short: Schedule I is not a set of scientific criteria, rationally applied to the world of drugs. Rather, it's a science-y looking smokescreen, one that allows the DEA to do virtually whatever it feels like -- which is often completely indefensible.

Image by Uomo vitruviano (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0), via Wikimedia Commons.

Related Tags
Constitutional Law, Robert A. Levy Center for Constitutional Studies

Stay Connected to Cato

Sign up for the newsletter to receive periodic updates on Cato research, events, and publications.

View All Newsletters

1000 Massachusetts Ave. NW
Washington, DC 20001-5403
202-842-0200
Contact Us
Privacy

Footer 1

  • About
    • Annual Reports
    • Leadership
    • Jobs
    • Student Programs
    • Media Information
    • Store
    • Contact
  • Podcasts

Footer 2

  • Experts
    • Policy Scholars
    • Adjunct Scholars
    • Fellows
  • Events
    • Upcoming
    • Past
    • Event FAQs
    • Sphere Summit

Footer 3

  • Publications
    • Books
    • Cato Journal
    • Regulation
    • Cato Policy Report
    • Cato Supreme Court Review
    • Cato’s Letter
    • Human Freedom Index
    • Economic Freedom of the World
    • Cato Handbook for Policymakers

Footer 4

  • Blog
  • Donate
    • Sponsorship Benefits
    • Ways to Give
    • Planned Giving
Also from Cato Institute:
Libertarianism.org
|
Humanprogress.org
|
Downsizinggovernment.org